JP2016535601A - 拡張性のある骨格筋系譜形成及び培養の方法 - Google Patents
拡張性のある骨格筋系譜形成及び培養の方法 Download PDFInfo
- Publication number
- JP2016535601A JP2016535601A JP2016552246A JP2016552246A JP2016535601A JP 2016535601 A JP2016535601 A JP 2016535601A JP 2016552246 A JP2016552246 A JP 2016552246A JP 2016552246 A JP2016552246 A JP 2016552246A JP 2016535601 A JP2016535601 A JP 2016535601A
- Authority
- JP
- Japan
- Prior art keywords
- cell line
- self
- differentiation
- cell
- species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 68
- 230000015572 biosynthetic process Effects 0.000 title description 24
- 210000002027 skeletal muscle Anatomy 0.000 title description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 31
- 210000004027 cell Anatomy 0.000 claims description 150
- 230000004069 differentiation Effects 0.000 claims description 55
- 230000001114 myogenic effect Effects 0.000 claims description 48
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 41
- 229960003722 doxycycline Drugs 0.000 claims description 34
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 34
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims description 29
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 29
- 108091023040 Transcription factor Proteins 0.000 claims description 28
- 102000040945 Transcription factor Human genes 0.000 claims description 26
- 210000000130 stem cell Anatomy 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 19
- 230000012010 growth Effects 0.000 claims description 17
- 101000958865 Homo sapiens Myogenic factor 5 Proteins 0.000 claims description 16
- 102100032970 Myogenin Human genes 0.000 claims description 16
- 102100038380 Myogenic factor 5 Human genes 0.000 claims description 15
- 244000144972 livestock Species 0.000 claims description 14
- 102100028914 Catenin beta-1 Human genes 0.000 claims description 13
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims description 13
- 230000001973 epigenetic effect Effects 0.000 claims description 12
- 101001023043 Homo sapiens Myoblast determination protein 1 Proteins 0.000 claims description 11
- 102100035077 Myoblast determination protein 1 Human genes 0.000 claims description 11
- -1 BIO Chemical compound 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 230000004156 Wnt signaling pathway Effects 0.000 claims description 9
- 210000003205 muscle Anatomy 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 230000004070 myogenic differentiation Effects 0.000 claims description 7
- 108010077544 Chromatin Proteins 0.000 claims description 6
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 claims description 6
- 102100040891 Paired box protein Pax-3 Human genes 0.000 claims description 6
- 210000003483 chromatin Anatomy 0.000 claims description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 5
- 244000144977 poultry Species 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 4
- 230000006718 epigenetic regulation Effects 0.000 claims description 4
- 235000012631 food intake Nutrition 0.000 claims description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 4
- 210000001087 myotubule Anatomy 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- 108010033040 Histones Proteins 0.000 claims description 3
- 102000006947 Histones Human genes 0.000 claims description 3
- 101000958866 Homo sapiens Myogenic factor 6 Proteins 0.000 claims description 3
- 101000601661 Homo sapiens Paired box protein Pax-7 Proteins 0.000 claims description 3
- 102100038379 Myogenic factor 6 Human genes 0.000 claims description 3
- 102100037503 Paired box protein Pax-7 Human genes 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 102000054767 gene variant Human genes 0.000 claims description 3
- 238000010362 genome editing Methods 0.000 claims description 3
- 210000001082 somatic cell Anatomy 0.000 claims description 3
- HPTXLHAHLXOAKV-INIZCTEOSA-N (2S)-2-(1,3-dioxo-2-isoindolyl)-3-(1H-indol-3-yl)propanoic acid Chemical compound O=C1C2=CC=CC=C2C(=O)N1[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 HPTXLHAHLXOAKV-INIZCTEOSA-N 0.000 claims description 2
- DXYYSGDWQCSKKO-UHFFFAOYSA-N 2-methylbenzothiazole Chemical compound C1=CC=C2SC(C)=NC2=C1 DXYYSGDWQCSKKO-UHFFFAOYSA-N 0.000 claims description 2
- MDYDGUOQFUQOGE-UHFFFAOYSA-N 2-methylpropanethioic acid S-[7-oxo-7-[(4-phenyl-2-thiazolyl)amino]heptyl] ester Chemical compound S1C(NC(=O)CCCCCCSC(=O)C(C)C)=NC(C=2C=CC=CC=2)=C1 MDYDGUOQFUQOGE-UHFFFAOYSA-N 0.000 claims description 2
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims description 2
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 claims description 2
- JHSXDAWGLCZYSM-UHFFFAOYSA-N 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide Chemical compound CC1=CC(Cl)=CC=C1OCCCC(=O)NO JHSXDAWGLCZYSM-UHFFFAOYSA-N 0.000 claims description 2
- DVNYTAVYBRSTGK-UHFFFAOYSA-N 5-aminoimidazole-4-carboxamide Chemical group NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 claims description 2
- RZWRYPGAUIOOMK-UHFFFAOYSA-N 5-nitroso-8-quinolinol Chemical compound C1=CN=C2C(O)=CC=C(N=O)C2=C1 RZWRYPGAUIOOMK-UHFFFAOYSA-N 0.000 claims description 2
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 claims description 2
- VUWMSJQZENJPHO-UHFFFAOYSA-N 7-oxo-7-(n-phenylanilino)heptanoic acid Chemical compound C=1C=CC=CC=1N(C(=O)CCCCCC(=O)O)C1=CC=CC=C1 VUWMSJQZENJPHO-UHFFFAOYSA-N 0.000 claims description 2
- 241001550224 Apha Species 0.000 claims description 2
- MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 230000007067 DNA methylation Effects 0.000 claims description 2
- 102000016680 Dioxygenases Human genes 0.000 claims description 2
- 108010028143 Dioxygenases Proteins 0.000 claims description 2
- 102000008157 Histone Demethylases Human genes 0.000 claims description 2
- 108010074870 Histone Demethylases Proteins 0.000 claims description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 claims description 2
- 108010036115 Histone Methyltransferases Proteins 0.000 claims description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 claims description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 claims description 2
- 102000003964 Histone deacetylase Human genes 0.000 claims description 2
- 108090000353 Histone deacetylase Proteins 0.000 claims description 2
- 102000016397 Methyltransferase Human genes 0.000 claims description 2
- 108060004795 Methyltransferase Proteins 0.000 claims description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims description 2
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 claims description 2
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 claims description 2
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims description 2
- 229950008805 abexinostat Drugs 0.000 claims description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 2
- 229960003094 belinostat Drugs 0.000 claims description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 2
- 210000000646 extraembryonic cell Anatomy 0.000 claims description 2
- YAEMHJKFIIIULI-UHFFFAOYSA-N n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea Chemical compound C1=CC(OC)=CC=C1CNC(=O)NC1=NC=C([N+]([O-])=O)S1 YAEMHJKFIIIULI-UHFFFAOYSA-N 0.000 claims description 2
- OYKBQNOPCSXWBL-SNAWJCMRSA-N n-hydroxy-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide Chemical compound ONC(=O)\C=C\C1=CC=CC(C(=O)NO)=C1 OYKBQNOPCSXWBL-SNAWJCMRSA-N 0.000 claims description 2
- 229960005184 panobinostat Drugs 0.000 claims description 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 2
- 238000007634 remodeling Methods 0.000 claims description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 2
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 2
- GOVYBPLHWIEHEJ-UHFFFAOYSA-N tubastatin A Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=C(C(=O)NO)C=C1 GOVYBPLHWIEHEJ-UHFFFAOYSA-N 0.000 claims description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000237 vorinostat Drugs 0.000 claims description 2
- 102000001267 GSK3 Human genes 0.000 claims 3
- 108060006662 GSK3 Proteins 0.000 claims 3
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims 3
- RFLHBLWLFUFFDZ-UHFFFAOYSA-N BML-210 Chemical compound NC1=CC=CC=C1NC(=O)CCCCCCC(=O)NC1=CC=CC=C1 RFLHBLWLFUFFDZ-UHFFFAOYSA-N 0.000 claims 1
- 101000589002 Homo sapiens Myogenin Proteins 0.000 claims 1
- KPNNXHVGOKRBEF-UHFFFAOYSA-N N-hydroxy-7-(2-naphthalenylthio)heptanamide Chemical compound C1=CC=CC2=CC(SCCCCCCC(=O)NO)=CC=C21 KPNNXHVGOKRBEF-UHFFFAOYSA-N 0.000 claims 1
- 238000009509 drug development Methods 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 235000013372 meat Nutrition 0.000 abstract description 21
- 238000004519 manufacturing process Methods 0.000 abstract description 17
- 235000013305 food Nutrition 0.000 abstract description 6
- 238000004113 cell culture Methods 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000014509 gene expression Effects 0.000 description 34
- 230000011712 cell development Effects 0.000 description 27
- 239000002609 medium Substances 0.000 description 26
- 230000006698 induction Effects 0.000 description 24
- 238000001262 western blot Methods 0.000 description 19
- 230000001939 inductive effect Effects 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 241000894007 species Species 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 108010056785 Myogenin Proteins 0.000 description 15
- 230000004913 activation Effects 0.000 description 13
- 238000001514 detection method Methods 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 210000000107 myocyte Anatomy 0.000 description 11
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 10
- 230000030833 cell death Effects 0.000 description 10
- 210000002242 embryoid body Anatomy 0.000 description 10
- 108010082117 matrigel Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108010085895 Laminin Proteins 0.000 description 9
- 102000007547 Laminin Human genes 0.000 description 9
- 241001529936 Murinae Species 0.000 description 9
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 239000011575 calcium Substances 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000005283 ground state Effects 0.000 description 8
- 102100036912 Desmin Human genes 0.000 description 7
- 108010044052 Desmin Proteins 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 230000001464 adherent effect Effects 0.000 description 7
- 210000005045 desmin Anatomy 0.000 description 7
- 210000003716 mesoderm Anatomy 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 6
- 108090000672 Annexin A5 Proteins 0.000 description 6
- 102000004121 Annexin A5 Human genes 0.000 description 6
- 102100029855 Caspase-3 Human genes 0.000 description 6
- 101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 6
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 6
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 6
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 6
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 230000008602 contraction Effects 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 235000013622 meat product Nutrition 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 5
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 229960002756 azacitidine Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 210000001778 pluripotent stem cell Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 210000002363 skeletal muscle cell Anatomy 0.000 description 5
- 238000004114 suspension culture Methods 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 102100038595 Estrogen receptor Human genes 0.000 description 4
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 4
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 4
- 241000286209 Phasianidae Species 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 102000013814 Wnt Human genes 0.000 description 4
- 108050003627 Wnt Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229930189065 blasticidin Natural products 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 4
- 235000013617 genetically modified food Nutrition 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000009495 transient activation Effects 0.000 description 4
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 3
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000025164 anoikis Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 230000025084 cell cycle arrest Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 230000002297 mitogenic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 210000002235 sarcomere Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 241000270722 Crocodylidae Species 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100021291 Methyl-CpG-binding domain protein 3 Human genes 0.000 description 2
- 101710111894 Methyl-CpG-binding domain protein 3 Proteins 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 241000270666 Testudines Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000003352 cell adhesion assay Methods 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 102000011941 human estrogen receptor alpha Human genes 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 230000003183 myoelectrical effect Effects 0.000 description 2
- 210000003365 myofibril Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- JCSGFHVFHSKIJH-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-4-(1-methyl-3-indolyl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C1=CC=C(Cl)C=C1Cl JCSGFHVFHSKIJH-UHFFFAOYSA-N 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010034320 GGCGCC-specific type II deoxyribonucleases Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 101150013833 MYOD1 gene Proteins 0.000 description 1
- 101710099061 Myogenic factor 5 Proteins 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102100024837 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 Human genes 0.000 description 1
- 101710188227 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 3 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000002236 cellular spheroid Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000001053 micromoulding Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000009753 muscle formation Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
- C12N2501/392—Sexual steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Abstract
Description
本願は、全体として参照により本明細書に取り込まれる、2013年10月30日出願の米国特許仮出願第61/962,068号の利益を主張するものである。
本願と共に提出されたASCIIテキストファイル(ファイル名:52553_136621_ST25.txt;サイズ:2,962バイト;及び作成日:2014年10月30日)内の電子出願による配列表の内容は、全体として参照により本明細書に取り込まれる。
本発明は、米国政府の支援により、米国国立衛生研究所により授与された認可番号R01HD069979/00032722の下でなされた。米国政府は、本発明において一定の権利を有する。
O2KM細胞株。O2KM細胞株は、親O2K細胞株から、MyoDERオープンリーティングフレーム配列(ORF)を含有するラスチジシン選択性導入遺伝子カセットのレンチウイルスでの挿入により得た。この実施例の節を参照すると、O2K細胞/細胞株とpiPSC細胞は、互換的に用いられている。図4Aに示されたレンチウイルスベクターを、PCR増幅されたMyoDER ORFを含有するpENTR/D−TOPOエントリーベクター(ライフ・テクノロジーズ #K2435−20)クローンから、attR1組換え部位とattR2組換え部位の間のpLentiCMVBlastデスティネーションベクター(アドジーン #17451)のCMVプロモータの下流のMyoDER ORF(アドジーン #13494)をクローニングすることにより調製した。レンチウイルス上清を調製するために、PolyJetトランスフェクション試薬(サイナゲン(Signagen) #SL100688)を用いて、293FT細胞を、調製されたpLentiCMVBlast[MyoDER]プラスミド、pMD2.Gエンベローププラスミド(アドジーン #12259)及びpsPAX2パッケージングプラスミド(アドジーン #12260)とコトランスフェクトした。O2Kに、293FT上清から濃縮されたシュードウイルスを形質導入した。形質導入されたO2Kを、フェノールレッド不含培地で培養して、10μg/mLブラスチシジンで4日間選択し、その後、15μg/mLブラスチシジンでさらに2日間選択した。選択された細胞は、O2KMと呼称した。O2KMストック中のMyoDERの発現を、ウェスタンブロットにより検証した(図4B)。
アポトーシス及び分化の軸はCHIR99021により調節される。図9は、(i.)自己複製環境における5%O2下、並びに(ii.)DOX、LIF及び3iの非存在下、20%O2の下で48時間後の、培養された基底状態piPSCコロニーの位相差画像を示す。図16は、培養物の24時間移行前および後のアポトーシス細胞のアネキシンV標識を示す。図17Aは、分化環境移行(12〜48時間)の前(0時間目)及び後(12〜48時間目)の基底状態コロニーにおける全長CPP32(約32kDプロカスパーゼ3a)及び大きな切断画分(約17kD切断されたカスパーゼ3a)のウェスタンブロット検出を示す。図9は、示された通りCHIR99021を補充された分化環境での48時間培養後の接着培養物(iii、iv、vi、及びvi)及び非接着性胚様体培養物(vii及びviii)の位相差画像を示す。図10は、100%に標準化された、基底状態(即ち、0時間目)培養物に対する48時間の、示されたCHIR99021を補充された分化環境培養物の接着細胞の割合を示す。* 胚様体として生存している非接着細胞。各培養条件についてn=3。図11は、示された通りCHIR99021を補充された分化環境へ培養物を24時間移行させた後のアポトーシス細胞のアネキシン標識を示す。図17Bは、示されたCHIR99021レベルの存在下で分化環境へ42時間移行させた後のコロニー内の全長CPP32及び切断画分のウェスタンブロット検出を示す。TUBAは、内部タンパク質負荷対照として検出されている。
要約すると、本開示に記載された例示的実施形態の特定の態様が、培養された食肉適用物について以下の予測されなかった利点の1つ以上を示すことが発見された:
(i)急速な細胞増殖速度;
(ii)急速な分化:インビトロで、17β−エストラジオールによるMyoDER活性化及びドキシサイクリン除去の48時間後という短時間で、O2KM細胞株が筋原性系譜に分化する。長過ぎる分化手順を必要としない;
(iii)効率的な分化:CHIR99021/5AC/MyoDERに方向づけられた系譜形成が、機能的骨格筋細胞への大規模で忠実性の高い変換を確実にする。細胞選別を必要としない;
(iv)無期限の自己複製:未分化O2KMの自己複製が厳密に施行され、自己複製環境で支援される;
(v)無血清培地中での自己複製及び最終分化:O2KM株の自己複製及び最終筋原性分化が、両者とも無血清培地で検証された;
(vi)胚様体としての浮遊培養系との適合性:多能性状態では、親O2K及び修飾されたO2KMが、アノイキスに耐性があり、浮遊培養において単一細胞から胚様体に培養され得る。O2KM由来胚様体は、培養された食肉生産のためのバイオプリンティング及びマイクロモールドなどの多細胞スフェロイド組立技術と適合性があり得る;そして
(vii)自己収縮:骨格筋として最終分化されたO2KMは、筋節の成熟及び自己収縮を呈する。このため筋線維成熟を促進するのに、外部刺激(例えば、機械的張力、アセチルコリン受容体活性化、電気刺激)が、必要とならない可能性がある。
Claims (28)
- 動物種の自己複製細胞株を筋原性転写因子で修飾して、筋原性転写因子修飾細胞株を生成すること、及び
前記修飾細胞株を外因性調節により誘導して、前記細胞株を自己複製工程に維持するか、又は前記細胞株を筋原性分化工程に進めること、
を含む、培養された筋組織を生成する方法。 - 前記筋組織が、家畜又は家禽種のものである、請求項1に記載の方法。
- 前記筋組織が、家畜種のものである、請求項2に記載の方法。
- 前記家畜種が、ブタ又はウシである、請求項3に記載の方法。
- 前記生成された筋組織が、ヒト及び非ヒトの食物消費に適合される、請求項1〜4のいずれか1項に記載の方法。
- 前記自己複製細胞株が、胚性幹細胞株、人工多能性幹細胞株、胚体外細胞株、及び体細胞株からなる群から選択される、請求項1〜5のいずれか1項に記載の方法。
- 前記自己複製幹細胞株が、家畜又は家禽種のものである、請求項6に記載の方法。
- 前記自己複製幹細胞株が、家畜種のものである、請求項7に記載の方法。
- 前記家畜種が、ブタ又はウシである、請求項8に記載の方法。
- 前記自己複製幹細胞株が、ヒト及び非ヒトの食物消費を意図した任意の動物種のものであり、任意のコンパニオンアニマルであり、及び/又は研究若しくは治療薬開発に用いられる任意の動物種のものである、請求項6〜9のいずれか1項に記載の方法。
- 前記筋原性転写因子が、MYOD1、MYOG、MYF5、MYF6、PAX3、PAX7、それらのパラログ、オーソログ、及び遺伝子変異体からなる群から選択される、請求項1〜10のいずれか1項に記載の方法。
- 前記筋原性転写因子が、MYOD1である、請求項1〜11のいずれか1項に記載の方法。
- 未分化細胞ストック増殖のために第1の培地中に前記修飾細胞株を維持することをさらに含む、請求項1〜12のいずれか1項に記載の方法。
- 細胞ストック増殖のためにドキシサイクリンを含む第1の培地中に前記修飾細胞株を維持することをさらに含む、請求項13に記載の方法。
- 系譜特異的な分化のために第2の培地中に前記修飾細胞株を移し替えることをさらに含む、請求項1〜14のいずれか1項に記載の方法。
- 系譜特異的な分化のためにE2を含む第2の培地中で前記修飾細胞株を処理することをさらに含む、請求項15に記載の方法。
- 前記第2の培地が、古典的WNTシグナル伝達経路を活性化する試薬、エピジェネティックな調節のための試薬、又はそれらの組合わせをさらに含む、請求項15又は16に記載の方法。
- 前記第2の培地が、古典的WNTシグナル伝達経路を活性化する試薬をさらに含む、請求項17に記載の方法。
- 前記古典的WNTシグナル伝達経路を活性化する試薬が、GSK3β阻害剤を含む、請求項18に記載の方法。
- 前記GSK3β阻害剤が、CHIR99021、塩化リチウム、BIO、CHIR99021、SB216763、CHIR−98014、TWS119、チデグルシブ、IM−12、1−アザケンパウロン(1-Azakenpullone)、AR−A014418、及びSB415286からなる群の1つ又は複数の構成員から選択される、請求項18に記載の方法。
- 前記GSK3β阻害剤が、CHIR99021である、請求項20に記載の方法。
- 前記第2の培地が、エピジェネティックな調節のための試薬をさらに含む、請求項17に記載の方法。
- 前記エピジェネティックモジュレータが、5AC、RG108、スクリプタイド、酪酸ナトリウム、トリコスタチンA、スベロイルアニリドヒドロキサム酸、MS−275、CI−994、BML−210、M344、MGCD0103、PXD101、LBH−589、ツバスタチンA、NSC3825、NCH−51、NSC−3852、HNHA、BML−281、CBHA、サレルミド、ピメリン酸ジフェニルアミド、ITF−2357、PCI−24781、APHA化合物8、ドロキシノスタット(Droxinostat)、SB−939、ヒストンデアセチラーゼパラログ、ヒストンアセチルトランスフェラーゼパラログ、tet−メチシトシンジオキシゲナーゼパラログ(tet-methycytosine dioxygenase paralogs)、ヒストンデメチラーゼパラログ、ヒストンメチルトランスフェラーゼパラログ、及びDNAメチルトランスフェラーゼパラログ、ヒストン、並びにMi−2/NuRD及びSWI/SNFを含むクロマチンリモデリング複合体のサブユニットからなる群の1つ又は複数の構成員から選択される、請求項22に記載の方法。
- 前記エピジェネティックモジュレータが、DNAメチル化の阻害剤である、請求項22又は23に記載の方法。
- 多核化された筋管を形成させることを含む、請求項1〜24のいずれか1項に記載の方法。
- 前記筋組織が、骨格筋線維を含む、請求項1〜25のいずれか1項に記載の方法。
- 前記古典的WNTシグナル伝達経路が、GSK3β又はその基質CTNNB1の遺伝子編集阻害により活性化される、請求項1〜26のいずれか1項に記載の方法。
- 請求項1〜27のいずれか1項に記載の方法により作製されるインビトロ生成の筋組織。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361962068P | 2013-10-30 | 2013-10-30 | |
US61/962,068 | 2013-10-30 | ||
PCT/US2014/063250 WO2015066377A1 (en) | 2013-10-30 | 2014-10-30 | Method for scalable skeletal muscle lineage specification and cultivation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020005873A Division JP2020089381A (ja) | 2013-10-30 | 2020-01-17 | 拡張性のある骨格筋系譜形成及び培養の方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016535601A true JP2016535601A (ja) | 2016-11-17 |
JP2016535601A5 JP2016535601A5 (ja) | 2017-12-07 |
JP6728049B2 JP6728049B2 (ja) | 2020-07-22 |
Family
ID=53005145
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016552246A Active JP6728049B2 (ja) | 2013-10-30 | 2014-10-30 | 拡張性のある骨格筋系譜形成及び培養の方法 |
JP2020005873A Pending JP2020089381A (ja) | 2013-10-30 | 2020-01-17 | 拡張性のある骨格筋系譜形成及び培養の方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020005873A Pending JP2020089381A (ja) | 2013-10-30 | 2020-01-17 | 拡張性のある骨格筋系譜形成及び培養の方法 |
Country Status (10)
Country | Link |
---|---|
US (3) | US20160251625A1 (ja) |
EP (1) | EP3071040B2 (ja) |
JP (2) | JP6728049B2 (ja) |
CN (2) | CN111154726A (ja) |
AU (2) | AU2014342180B2 (ja) |
BR (1) | BR112016009803B1 (ja) |
CA (1) | CA2928726A1 (ja) |
ES (1) | ES2782380T5 (ja) |
IL (2) | IL296889A (ja) |
WO (1) | WO2015066377A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020523015A (ja) * | 2017-06-07 | 2020-08-06 | ワイルド タイプ,インク. | エクスビボでの食肉の生産 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2782380T5 (es) | 2013-10-30 | 2023-05-08 | Univ Missouri | Método de especificación y cultivo de linaje del músculo esquelético escalable |
WO2017100498A1 (en) | 2015-12-11 | 2017-06-15 | The Johns Hopkins University | Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy |
WO2017124100A1 (en) * | 2016-01-14 | 2017-07-20 | Memphis Meats, Inc. | Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process |
EP3481191A2 (en) | 2016-07-11 | 2019-05-15 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Systems and methods for growing cells in vitro |
EP3612623A4 (en) | 2017-05-06 | 2021-06-23 | Memphis Meats, Inc. | COMPOSITIONS AND METHODS FOR INCREASING THE CULTURE DENSITY OF A CELLULAR BIOMASS IN A CULTURE INFRASTRUCTURE |
WO2019014652A1 (en) | 2017-07-13 | 2019-01-17 | Memphis Meats, Inc. | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CELL CULTURES USED IN FOOD PRODUCTION |
GB2573327B (en) * | 2018-05-03 | 2021-05-12 | Mosa Meat Bv | Apparatus and process for production of tissue from cells |
CN117701496A (zh) | 2019-05-28 | 2024-03-15 | 阿普赛德食品公司 | 制备可食用肉制品的方法 |
US11147300B2 (en) | 2019-11-20 | 2021-10-19 | Upside Foods, Inc. | Apparatuses and systems for preparing a meat product |
AU2020396360A1 (en) * | 2019-12-02 | 2022-06-16 | Avant Meats Company Limited | Methods of meat production by in vitro cell cultivation |
US20210235733A1 (en) | 2020-02-04 | 2021-08-05 | Memphis Meats, Inc. | Characteristics of meat products |
US20220073870A1 (en) | 2020-06-05 | 2022-03-10 | Upside Foods, Inc. | Nutrient media for the production of slaughter-free meat |
GB202008821D0 (en) * | 2020-06-10 | 2020-07-22 | Highersteaks Ltd | Systems and methods for cell conversion |
US20220056394A1 (en) | 2020-08-18 | 2022-02-24 | Upside Foods, Inc. | Systems, devices, and methods for sterilizing bioreactors and culture media |
US20220195368A1 (en) * | 2020-12-21 | 2022-06-23 | Upside Foods, Inc. | Fluid conduit with radial expansion of fluid flow |
US11912967B2 (en) * | 2020-12-22 | 2024-02-27 | Upside Foods, Inc. | Systems and methods for cultivating tissue on porous substrates |
WO2022156939A1 (en) * | 2021-01-22 | 2022-07-28 | HigherSteaks Limited | Products for cell conversion |
WO2022216742A1 (en) | 2021-04-07 | 2022-10-13 | Upside Foods, Inc. | Generation of cell-based products for consumption that comprise proteins derived from exotic, endangered, and extinct species |
US20220369665A1 (en) | 2021-04-28 | 2022-11-24 | Upside Foods, Inc. | Generation of Cell-Based Products for Human Consumption |
WO2022234586A1 (en) | 2021-05-06 | 2022-11-10 | Yeda Research And Development Co. Ltd. | Method for inducing hypertrophic muscle fibers for industrial meat production |
IL308773A (en) | 2021-06-16 | 2024-01-01 | Upside Foods Inc | Scaffolds based on vegetable fat for growing meats based on cells and methods for producing such products |
BR112023026380A2 (pt) | 2021-07-09 | 2024-03-05 | Supreme | Gêneros alimentícios compreendendo células diferenciadas a partir de células-tronco oligopotentes engenheiradas |
WO2023069991A1 (en) | 2021-10-19 | 2023-04-27 | Eat Scifi Inc. | Plant base/animal cell hybrid meat substitute |
WO2023122688A1 (en) * | 2021-12-23 | 2023-06-29 | Upside Foods, Inc. | Scaling up myogenic tissue: late passage myogenicity |
EP4292440A1 (en) | 2022-06-14 | 2023-12-20 | Upside Foods, Inc. | Suspension based chicken product formulation |
EP4293109A1 (en) | 2022-06-14 | 2023-12-20 | Upside Foods, Inc. | Non-skeletal muscle-derived cells as a source of suspension capable myogenic cells for cultured foods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013081783A (ja) * | 2011-10-11 | 2013-05-09 | Bond University Ltd | カスタマイズされた組成物およびその使用 |
WO2013073246A1 (en) * | 2011-11-18 | 2013-05-23 | Kyoto University | Method of inducing differentiation from pluripotent stem cells to skeletal muscle cells |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510254A (en) | 1986-04-18 | 1996-04-23 | Advanced Tissue Sciences, Inc. | Three dimensional cell and tissue culture system |
IE904639A1 (en) * | 1989-12-21 | 1991-07-17 | Univ Georgia | Bovine myogenic factor gene |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
WO1999031222A1 (en) | 1997-12-18 | 1999-06-24 | Willem Frederik Van Eelen | Industrial scale production of meat from in vitro cell cultures |
WO1999043786A2 (en) | 1998-02-27 | 1999-09-02 | Purdue Research Foundation | Submucosa gel compositions |
US6537782B1 (en) | 1998-06-01 | 2003-03-25 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
US6835390B1 (en) | 2000-11-17 | 2004-12-28 | Jon Vein | Method for producing tissue engineered meat for consumption |
DE102004017484B4 (de) | 2004-04-08 | 2006-07-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Herstellung einer biologischen Materialzusammensetzung tierischen Ursprungs |
US20060121006A1 (en) | 2004-09-10 | 2006-06-08 | Chancellor Michael B | Production of nutritional and therapeutic products from cultured animal cells |
AU2004324099B2 (en) | 2004-09-17 | 2011-02-03 | Jon Vein | Tissue engineered meat for consumption and a method for producing tissue engineered meat for consumption |
AU2006310690B2 (en) * | 2005-11-02 | 2012-05-31 | Société des Produits Nestlé S.A. | Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use |
US20110191871A1 (en) * | 2006-02-28 | 2011-08-04 | Trustees Of Boston University | Methods to identify factors associated with muscle growth and uses thereof |
DE102007029699B4 (de) | 2007-06-27 | 2010-12-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Isolierte proliferierende Zellen mit Stammzelleigenschaften aus adultem Gewebe von wechselwarmen Wirbeltieren, stabile Zellkulturen davon und Verfahren zu deren Herstellung |
CN101624570B (zh) | 2008-07-07 | 2011-04-13 | 刘志军 | 中药培养养殖肉灵芝方法及养殖肉灵芝保健品的制备方法 |
WO2010068897A2 (en) | 2008-12-12 | 2010-06-17 | Kedar Challakere | Stem cell enhanced protein products and uses thereof |
US20110091604A1 (en) | 2009-10-21 | 2011-04-21 | Seth Adrian Miller | Synthetic meat |
US8883502B2 (en) | 2010-09-09 | 2014-11-11 | The Regents Of The University Of California | Expandable cell source of neuronal stem cell populations and methods for obtaining and using them |
BR112013031770A2 (pt) * | 2011-06-10 | 2016-12-06 | Univ Georgia | população de células-tronco aviárias de pluripotência induzida, ave quimérica, método de reprogamação de uma célula embrionária aviária ou célula somática adulta, método de manipulação genética de espécies aviárias, método de instilar a resistência à doença em uma célula-tronco aviária pluripotente induzida, método de instilar a resistência à doença em uma população de célula-tronco aviária pluripotente, método para produzir um gameta de ave quimérica, método de produção de material imunogênico para uma vacina e vacina |
CA2780087A1 (en) | 2011-06-14 | 2012-12-14 | Jacques P. Tremblay | Myogenic differentiation of stem cells and uses thereof |
WO2012176023A1 (en) | 2011-06-23 | 2012-12-27 | Indian Institute Of Technology Kanpur | Hydrogel scaffolds for tissue engineering |
EP2731446A4 (en) | 2011-07-12 | 2015-04-15 | METHOD AND COMPOSITIONS FOR CONSUMABLE MATERIALS | |
WO2013016547A2 (en) | 2011-07-26 | 2013-01-31 | The Curators Of The University Of Missouri | Engineered comestible meat |
US10039306B2 (en) | 2012-03-16 | 2018-08-07 | Impossible Foods Inc. | Methods and compositions for consumables |
US9737875B2 (en) | 2012-03-16 | 2017-08-22 | Impossible Foods Inc. | Affinity reagents for protein purification |
CN104603293A (zh) | 2012-03-28 | 2015-05-06 | 现代牧场有限公司 | 工程的皮革和其制造方法 |
BR112015016651A2 (pt) | 2013-01-11 | 2017-07-11 | Impossible Foods Inc | réplica de queijo não láctea compreendendo um coacervado |
HUE056638T2 (hu) | 2013-02-22 | 2022-02-28 | Univ Leland Stanford Junior | Telomer kiterjesztéssel kapcsolatos gyógyászati alkalmazás |
WO2015038988A1 (en) | 2013-09-13 | 2015-03-19 | Modern Meadow, Inc. | Edible and animal-product-free microcarriers for engineered meat |
ES2782380T5 (es) | 2013-10-30 | 2023-05-08 | Univ Missouri | Método de especificación y cultivo de linaje del músculo esquelético escalable |
US9526267B2 (en) | 2014-04-17 | 2016-12-27 | Savage River, Inc. | Nutrient-dense meat structured protein products |
US20150296834A1 (en) | 2014-04-17 | 2015-10-22 | Savage River, Inc. dba Beyond Meat, Inc. | Plant based meat structured protein products |
MX2018000941A (es) | 2015-07-24 | 2019-08-29 | Synthetic Genomics Inc | Ingrediente alimenticio rico en proteinas a partir de biomasa y metodos de produccion. |
WO2017124100A1 (en) | 2016-01-14 | 2017-07-20 | Memphis Meats, Inc. | Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process |
EP3612623A4 (en) | 2017-05-06 | 2021-06-23 | Memphis Meats, Inc. | COMPOSITIONS AND METHODS FOR INCREASING THE CULTURE DENSITY OF A CELLULAR BIOMASS IN A CULTURE INFRASTRUCTURE |
WO2019014652A1 (en) | 2017-07-13 | 2019-01-17 | Memphis Meats, Inc. | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF CELL CULTURES USED IN FOOD PRODUCTION |
-
2014
- 2014-10-30 ES ES14858383T patent/ES2782380T5/es active Active
- 2014-10-30 CN CN202010084479.7A patent/CN111154726A/zh active Pending
- 2014-10-30 CA CA2928726A patent/CA2928726A1/en active Pending
- 2014-10-30 IL IL296889A patent/IL296889A/en unknown
- 2014-10-30 WO PCT/US2014/063250 patent/WO2015066377A1/en active Application Filing
- 2014-10-30 CN CN201480061537.7A patent/CN105899079A/zh not_active Withdrawn
- 2014-10-30 JP JP2016552246A patent/JP6728049B2/ja active Active
- 2014-10-30 BR BR112016009803-0A patent/BR112016009803B1/pt active IP Right Grant
- 2014-10-30 US US15/033,207 patent/US20160251625A1/en not_active Abandoned
- 2014-10-30 AU AU2014342180A patent/AU2014342180B2/en active Active
- 2014-10-30 EP EP14858383.4A patent/EP3071040B2/en active Active
-
2016
- 2016-04-20 US US15/134,252 patent/US10920196B2/en active Active
- 2016-04-24 IL IL245292A patent/IL245292B2/en unknown
-
2019
- 2019-04-02 AU AU2019202244A patent/AU2019202244B2/en active Active
-
2020
- 2020-01-17 JP JP2020005873A patent/JP2020089381A/ja active Pending
-
2021
- 2021-02-12 US US17/175,324 patent/US20210171912A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013081783A (ja) * | 2011-10-11 | 2013-05-09 | Bond University Ltd | カスタマイズされた組成物およびその使用 |
WO2013073246A1 (en) * | 2011-11-18 | 2013-05-23 | Kyoto University | Method of inducing differentiation from pluripotent stem cells to skeletal muscle cells |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020523015A (ja) * | 2017-06-07 | 2020-08-06 | ワイルド タイプ,インク. | エクスビボでの食肉の生産 |
Also Published As
Publication number | Publication date |
---|---|
JP6728049B2 (ja) | 2020-07-22 |
IL245292B (en) | 2022-10-01 |
CN105899079A (zh) | 2016-08-24 |
US20160251625A1 (en) | 2016-09-01 |
US20160227830A1 (en) | 2016-08-11 |
EP3071040B1 (en) | 2020-01-01 |
AU2019202244A1 (en) | 2019-04-18 |
CN111154726A (zh) | 2020-05-15 |
WO2015066377A1 (en) | 2015-05-07 |
AU2014342180A1 (en) | 2016-05-19 |
AU2014342180B2 (en) | 2019-01-03 |
EP3071040B2 (en) | 2022-12-28 |
US20210171912A1 (en) | 2021-06-10 |
IL245292B2 (en) | 2023-02-01 |
BR112016009803A8 (pt) | 2018-01-30 |
IL245292A0 (en) | 2016-06-30 |
US10920196B2 (en) | 2021-02-16 |
JP2020089381A (ja) | 2020-06-11 |
EP3071040A4 (en) | 2017-06-21 |
BR112016009803B1 (pt) | 2022-02-08 |
CA2928726A1 (en) | 2015-05-07 |
IL296889A (en) | 2022-12-01 |
EP3071040A1 (en) | 2016-09-28 |
ES2782380T5 (es) | 2023-05-08 |
BR112016009803A2 (pt) | 2017-12-05 |
ES2782380T3 (es) | 2020-09-14 |
AU2019202244B2 (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6728049B2 (ja) | 拡張性のある骨格筋系譜形成及び培養の方法 | |
US20170313989A1 (en) | Inhibition and enhancement of reprogramming by chromatin modifying enzymes | |
US9115345B2 (en) | MicroRNA induction of pluripotential stem cells and uses thereof | |
CA2956108A1 (en) | Enhanced reprogramming to ips cells | |
Mezentseva et al. | The histone methyltransferase inhibitor BIX01294 enhances the cardiac potential of bone marrow cells | |
US20220364058A1 (en) | Method For Promoting Differentiation Of Pluripotent Stem Cells By Reducing Undifferentiated State Thereof | |
Mo et al. | Generation and characterization of bat-induced pluripotent stem cells | |
EP4048282A1 (en) | Cortical neural progenitor cells from ipscs | |
Han et al. | SCNT versus iPSCs: proteins and small molecules in reprogramming. | |
Wilson et al. | Major regulatory factors in the evolution of development: the roles of goosecoid and Msx in the evolution of the direct‐developing sea urchin Heliocidaris erythrogramma | |
WO2017073763A1 (ja) | 多能性幹細胞の分化抵抗性を減弱する方法 | |
Kim et al. | Protein kinase A signaling is inhibitory for reprogramming into pluripotent stem cells | |
WO2013100140A1 (ja) | 生殖細胞からの多能性幹細胞様細胞の誘導 | |
CA3221942A1 (en) | Foodstuffs comprising cells differentiated from engineered oligopotent stem cells | |
Lewandoski et al. | Developmental biology: extending the limb and body with vectors and scalars | |
Autio | Investigating the Regulation of Distinct Epigenetic States in Human Embryonic Stem Cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171030 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171030 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190402 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190917 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200305 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200325 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200602 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200701 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6728049 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |